About Synergen Technologies
Synergen Technologies develops platform polymer technologies that can be utilized for coatings and adhesive applications including coating tabaims to let & capsules to control the time release of drugs and their dosage.
Synergen Technologies Frequently Asked Questions (FAQ)
Where is Synergen Technologies's headquarters?
Synergen Technologies's headquarters is located at 2201 West Campbell Park Dr Ste 16, Chicago.
What is Synergen Technologies's latest funding round?
Synergen Technologies's latest funding round is Incubator/Accelerator.
Who are the investors of Synergen Technologies?
Investors of Synergen Technologies include Chicago Technology Park.
Who are Synergen Technologies's competitors?
Competitors of Synergen Technologies include Intarcia Therapeutics and 4 more.
Compare Synergen Technologies to Competitors
Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.
Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.
PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.
NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.
Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.
Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.